Navigation Links
NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study
Date:11/4/2008

results suggest that naproxcinod could represent a valuable treatment alternative for osteoarthritis patients," said Raymond Townsend, Professor of Medicine at the University of Pennsylvania, who advised NicOx on the design and analysis of the study. "The hypertensive side effects of COX-2 inhibitors and traditional NSAIDs are a serious medical issue and there is a clear need for a new drug with no detrimental effect on blood pressure. These ABPM data have been obtained in a relevant population of chronically treated osteoarthritis patients with many cardiovascular risk factors and clearly show a consistent beneficial effect on blood pressure for naproxcinod across the dose range, in contrast to naproxen. In addition, the use of the ABPM technique gives them considerable weight, as it is widely recognized as the gold standard method for assessing the blood pressure profile of new drugs."

The 111 study design and results

In the study, 118 patients were randomized on a 1:1 basis to receive naproxcinod or naproxen, with escalating doses every three weeks. The trial included three doses of naproxcinod (375 mg bid, 750 mg bid and a supra-therapeutic dose of 1125 mg bid), which were compared to naproxen (250, 500 and 750 mg bid). 24-hour blood pressure monitoring was conducted at baseline and at the end of each three-week dose escalation (i.e. at the end of week 3, 6 and 9), using an FDA validated, ABPM device.

The primary objective of the study was to characterize the 24-hour arterial blood pressure profile of the three doses of naproxcinod, as measured by ABPM after each dose, compared to naproxen. At all time points, naproxcinod showed a decrease in the mean 24-hour SBP and DBP from baseline in contrast to naproxen. In terms of the overall treatment effect, as an average over week 3, 6 and 9, naproxen raised SBP by 1.5 mmHg from baseline, while naproxcinod lowered it by 2.3 mmHg, resulting in a difference between the two treatments of 3.8 mmHg (p=
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

1082

GOOD

Page: 1 2 3 4

Related medicine technology :

1. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
2. NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
3. NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients
4. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
5. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
6. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
7. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
8. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
9. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
10. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
11. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 24, 2013 The potential of ... delivery of therapeutic agents has been receiving undeniable attention ... showing significant promise. The crucial formulation considerations for orally ... play a major role in the efficiency of pulmonary ... development of new formulation techniques and devices in recent ...
(Date:5/23/2013)... DIEGO , May 23, 2013 Neurocrine Biosciences, ... Kevin Gorman , President and Chief Executive Officer ... 38 th Annual dbAccess Health Care Conference in Boston.   ... May 30 at 11:20 a.m. Eastern Time / 8:20 a.m. ... accessed on the Company,s website at http://www.neurocrine.com . ...
(Date:5/23/2013)... , May 23, 2013  MGC Diagnostics Corporation ... global medical technology company, today scheduled a conference call ... of fiscal year 2013, ended April 30, 2013. The ... May 30, 2013. The Company will report financial results ... the markets close on Thursday, May 30, 2013. ...
Breaking Medicine Technology:Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2
... 22, 2011 Regeneron Pharmaceuticals, Inc. (NASDAQ: ... Food and Drug Administration (FDA) has accepted for review ... Injection for Subcutaneous Use for the prevention of gout ... Prescription Drug User Fee Act (PDUFA), the goal for ...
... Endoscopy, Inc.,s (OTCPK: SNDY) is pleased to announce that ... of $73,895.  Solos Endoscopy has consummated agreements which resulted ... Three Months period ending September 30, 2011.  The signed ... reduction of ongoing expenses by approximately $40,000 per quarter. ...
Cached Medicine Technology:Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 2Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 3Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 4Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 5Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 6Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 7Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 8Solos Endoscopy Finishes the 3rd Quarter With a Net Profit 2
(Date:5/25/2013)... (PRWEB) May 25, 2013 While some ... those who have died serving our Country, many others ... prolonged partying and recklessness. The DUI attorneys at MacGregor ... DUI checklist to help keep this weekend’s party-goers out ... System , there were more than 950 fatal alcohol-related ...
(Date:5/25/2013)... Life science and analytical reagents are those ... create a new substance with the purpose of making ... as biotechnology reagents. Such reagents are significant in the ... market is driven by factors such as expansion in ... growth in research and rapid commercialization of such products. ...
(Date:5/25/2013)... (HealthDay News) -- Many viruses and parasites that affect ... -- a bacteria-borne illness than can result in liver ... parks, according to a veterinarian. These germs ... the air, said Dr. Susan Nelson, a clinical associate ... of these serious diseases can be fatal, even with ...
(Date:5/25/2013)... 2013 Studies from Johns Hopkins University ... excessive weight and their inability to get adequate sleep. ... weight can naturally relieve many symptoms. , Johns ... sleep quality was significantly associated with overall weight loss, ... dated November 6th, 2012, researchers monitored 77 participants ...
(Date:5/25/2013)... Pradaxa lawsuits filed on ... internal bleeding while using the blood thinner continue to mount ... District of Illinois, Bernstein Liebhard LLP reports. According to ... claims had been filed in the litigation as ... reported by the Court on May 15th. ( In Re: ...
Breaking Medicine News(10 mins):Health News:Criminal Attorneys Provide Memorial Day Weekend DUI Checklist and Safety Information 2Health News:Criminal Attorneys Provide Memorial Day Weekend DUI Checklist and Safety Information 3Health News:Life Sciences And Analytical Reagents Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research 2Health News:Life Sciences And Analytical Reagents Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research 3Health News:Hidden Dangers Dog Dog Parks 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3
... better preventive care, , THURSDAY, Nov. 19 (HealthDay News) -- ... lives, but only 25 percent of adults aged 50 to ... a new report shows. , Prepared by the U.S. Centers ... Association, the report also lays out ways to improve the ...
... more likely to have post-operative complications than those of ... fibroids, according to a study at Henry Ford Hospital. ... leaving the uterus intact and preserving the ability for ... patient can present difficulties for the most experienced gynecologic ...
... ... revitalized and interactive website Monday, November 16, 2009. The new site will be able ... initiated to provide users with an enhanced shopping and ordering experience. , ... (PRWEB) November 18, 2009 -- The new website ...
... , MELVILLE, N.Y., Nov. 19 Long Island IVF, a ... help patients achieve successful pregnancies, is now offering a new ... fertility treatment. Through this program and a partnership with In ... the amount of money couples pay for their comprehensive treatment ...
... and iron deficiency in schoolchildren could be reduced in her ... to be published in the International Journal of Food ... not only cheaper and more readily available than beef but ... Home Economics, at the University of Uyo, has looked at ...
... ... that will be marketed and sold through international distribution channels alongside the Company,s ... ... Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy ...
Cached Medicine News:Health News: Too Few Older Adults Get Recommended Screenings 2Health News: Too Few Older Adults Get Recommended Screenings 3Health News:Patient's weight not linked to success of fibroid surgery 2Health News:Great Customer Service Just Got Better as Emedco Announces the Launch of their Completely Updated and Enhanced Website 2Health News:Great Customer Service Just Got Better as Emedco Announces the Launch of their Completely Updated and Enhanced Website 3Health News:Long Island IVF to Offer IVF Financial Share Program, Limiting Costs and Providing Refunds if IVF is Not Successful 2Health News:Let them eat snail 2Health News:Nutra Pharma Introduces Chronic Pain Reliever, Nyloxin OTC, for International Distribution 2Health News:Nutra Pharma Introduces Chronic Pain Reliever, Nyloxin OTC, for International Distribution 3
... eliminate false signals and contamination caused ... Promega Barrier Tips offer performance and ... acids (PCR(a)), radioactive isotopes, tissue culture ... specimens. , Promega Barrier Tips are ...
Diamond Filter Tips play a critical role in preventing aerosol-borne contamination. Also available sterilized (no need to autoclave) and certified free of detectable RNase, DNase, DNA, RNA, and prote...
... contamination, which causes false ... Hydrophobic, nonwicking and self-sealing ... pass through these aerosol-resistant ... to tips with absorption ...
... Filters are ideal for PCR ... for any work where aerosol ... designed for pipetting DNA/RNA solutions, ... other. For applications requiring absolute ...
Medicine Products: